Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy”

Authors:

Abstract
We thank Gonzales et al for their valuable comments on the article on biomarkers from The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. 1 The RELY trial included 18 113 patients with atrial fibrillation, cardiac biomarkers were analyzed from plasma samples obtained at randomization in 6189 of the participants. The results showed that both N-terminal pro-Btype natriuretic peptide (NT-proBNP) and troponin I were strongly and independently related to thromboembolic outcomes regardless of clinical risk factors including heart failure. At randomization, all patients were classified as either having heart failure or not based on New York Heart Association class and on available information regarding previous measurements of left ventricular ejection fraction based on echocardiography, radionuclide, or angiogram assessments. 2 NT-proBNP is a sensitive biomarker of left ventricular function, clinical heart failure, and a predictor of adverse cardiac events in several patient populations. However, there is no close association between the degree of impaired left ventricular ejection fraction and the risk of thromboembolic events in patients with atrial fibrillation and heart failure. 3 In the RELY trial, blood samples for NT-proBNP analysis were collected at randomization and should not be significantly affected by hemodynamically relevant valve disease, because such patients were excluded from the trial. 2 However, information regarding left atrial anatomy and function, which are established risk factors for thromboembolic risk in atrial fibrillation, was not routinely collected in the RELY trial. As discussed in the article, we agree with Gonzales et al that a possible association between atrial function and NT-proBNP levels might contribute to the association between the NT-proBNP level and thromboembolic events. At present, guidelines recommend screening of patients who have newly detected atrial fibrillation with echocardiography to identify underlying structural pathologies and potential reversible causes of atrial fibrillation and also to tailor treatments. 4 However, for prediction of risk of thromboembolic events, a complementary measurement of NT-proBNP is attractive as an easily available tool to provide further guidance on management.